Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab,…
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its Elecsys® PRO-C3 test, a new diagnostic tool developed in collaboration with Nordic Bioscience, to assess the severity of…
Global Health Inequities Slashing Lifespans by Decades, WHO Warns A new report by the World Health Organization (WHO) reveals that the root causes of poor health often lie outside the…
Teva and Alvotech Expand U.S. Biosimilar Portfolio with Approval for SELARSDI™ Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) have…
WHO Highlights the Importance of Hand Hygiene Over Gloves on World Hand Hygiene Day Hand hygiene remains one of the most effective, affordable, and universal tools in preventing the spread…
73% of healthcare professionals (HCPs) report a disconnect between the availability of cutting-edge treatments and their effective implementation in clinical practice, while 3 in 4 oncologists say the rapid pace…
TREMFYA® Shows Sustained Long-Term Remission in Ulcerative Colitis Patients, According to Phase 3 QUASAR LTE Study More than 70% of patients in clinical remission and over 40% in endoscopic remission…
GSK to Present 43 Abstracts Across Respiratory Portfolio at ATS 2025, Including New Data on Mepolizumab and Depemokimab GSK plc (LSE/NYSE: GSK) today announced that 43 abstracts, including four late-breaking…
Sanofi Showcases Expansive Respiratory Innovation and Scientific Leadership at ATS 2025 with Robust Clinical Data from Dupixent and Immunology Pipeline Sanofi is poised to make a major impact at the…
Amgen Posts Strong First Quarter 2025 Financial Results, Driven by Robust Product Demand and Strategic Launches Amgen Inc. (NASDAQ: AMGN) reported its financial results for the first quarter of 2025,…
AstraZeneca’s Breztri Achieves Primary Endpoints in KALOS and LOGOS Phase III Trials, Marking a Significant Advance in the Treatment of Uncontrolled Asthma AstraZeneca announced encouraging high-level results from its pivotal…